当前位置:
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Epigenetic Therapy in a Rare Ovarian Cancer — A Double-Edged Sword
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2024-08-22 , DOI: 10.1056/nejmc2407971 Charles Hsu 1 , Jason A Konner 1 , Mrinal M Gounder 1
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2024-08-22 , DOI: 10.1056/nejmc2407971 Charles Hsu 1 , Jason A Konner 1 , Mrinal M Gounder 1
Affiliation
A woman with a rare ovarian tumor driven by EZH2 activity responded to tazemetostat, an EZH2 inhibitor, but T-cell acute lymphoblastic leukemia later developed.
中文翻译:
罕见卵巢癌的表观遗传治疗——一把双刃剑
一名患有由 EZH2 活性驱动的罕见卵巢肿瘤的女性对 EZH2 抑制剂他泽美司他有反应,但随后出现了 T 细胞急性淋巴细胞白血病。
更新日期:2024-08-22
中文翻译:
罕见卵巢癌的表观遗传治疗——一把双刃剑
一名患有由 EZH2 活性驱动的罕见卵巢肿瘤的女性对 EZH2 抑制剂他泽美司他有反应,但随后出现了 T 细胞急性淋巴细胞白血病。